Development of new business fields in the Equipment Development Business
First written in FY2019-Q1. 22 of 32 entries say "Advanced", first in FY2019-Q2. Latest entry: FY2026.
The whole theme swung hardest in 2019: 3 of 37 companies on the "Worse" side.
35 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「As a result, during the fiscal year, the company delivered 2 PAP units for diamond polishing to domestic customers.」
The company is developing PAP, ECMP, CARE and PCVM as its 4 priority processes and reached the stage of delivering 2 PAP units for diamond polishing. It is also proceeding with mass-production sales of PCVM, customer prototype evaluations for CARE and development for GaN applications. - FY2026-H1AdvancedAnnual report
「The company will proceed with prototype evaluations for existing customers and efforts to identify prospective customers, with the aim of receiving orders early.」
For surface processing equipment using PCVM, PAP, CARE and ECMP, the company is conducting prototype evaluations for existing customers and developing prospective customers, with the aim of receiving orders early. It is also proceeding with the addition of PAP prototype units and the introduction of an ECMP prototype and development unit. - FY2025-H1AdvancedAnnual report
「As a result, the company received an order for 1 Plasma Assisted Polishing unit.」
The company continues development, commercialization and sales activities for surface processing equipment for semiconductor materials, including PCVM, PAP, CARE and ECMP, and reached the stage of receiving an order for 1 Plasma Assisted Polishing unit. - FY2024AdvancedAnnual report
「The company received orders for 2 Plasma Chemical Vapor Machining (PCVM) units, comprising 1 small development unit and 1 large automated mass-production unit, and delivered both in the fourth quarter.」
The company received orders for 2 PCVM units, comprising a small development unit and a large automated mass-production unit, and delivered them and recognized the related revenue in the fourth quarter. - FY2024-Q3AdvancedAnnual report
「For the equipment business applying nan surface processing technologies targeting various semiconductor materials, the company is promoting the development and commercialization of equipment incorporating Catalytic Assisted Reactive Etching (CARE), Plasma Assisted Polishing (PAP), Plasma Chemical Vapor Machining (PCVM) and Electrochemical Mechanical Polishing (ECMP), an efficient surface polishing technology using anodic oxidation.」
The company has progressed to the stage of developing and commercializing equipment incorporating ECMP in addition to the existing CARE, PAP and PCVM technologies. Test-processing projects using next-generation processing and polishing equipment are also contributing to performance. - FY2024-Q2AdvancedAnnual report
「For the equipment business incorporating nan surface processing technologies targeting various semiconductor materials, including Catalytic Assisted Reactive Etching (CARE), Plasma Assisted Polishing (PAP) and Plasma Chemical Vapor Machining (PCVM), the company is promoting commercialization, order-taking and sales activities. It has received requests for test processing from multiple companies and numerous inquiries, leading to an expansion in the number of prospective customers. The company expects these activities to contribute to performance from the second half onward.」
The company continues commercialization, order-taking and sales activities for equipment incorporating CARE, PAP and PCVM, and has received test-processing requests from multiple companies and numerous inquiries, expanding its prospective customer base. It plans for these activities to contribute to performance from the second half onward. - FY2024-Q1RestatedAnnual report
「Sales in this business are also expected to be weighted toward the second half of the fiscal year. Toward the second half, the Company plans to sell large-scale automated cell culture systems in the life sciences business and next-generation processing and polishing equipment, the priority field of the equipment development business, including PAP, CARE and PCVM.」
The company continues its policy of identifying PAP, CARE and PCVM as priority areas of the Equipment Development Business and planning second-half sales together with large automated cell culture systems. - FY2023-Q3AdvancedAnnual report
「Toward the end of the fiscal year, the company is promoting the commercialization, order-taking and sales of equipment incorporating nan surface processing technologies primarily targeting semiconductor materials, including Catalytic Assisted Reactive Etching (CARE), Plasma Assisted Polishing (PAP) and Plasma Chemical Vapor Machining (PCVM). It has already received an order for a development unit related to next-generation polishing equipment. Following its exhibition at SEMICOM Japan 2022, held at the end of the second quarter, the company has received requests for test processing from multiple companies and has gradually achieved results, including the conclusion of a joint development agreement with a major company.」
The company is promoting the commercialization, order-taking and sales of equipment incorporating CARE, PAP and PCVM, progressing to an order for a development unit for next-generation polishing equipment, test-processing requests from multiple companies and the conclusion of a joint development agreement with a major company. - FY2023-Q2AdvancedAnnual report
「For the second half of the fiscal year, the company is promoting commercialization and order-taking activities in the priority new business fields of the Equipment Development Business, including equipment related to Catalytic Assisted Reactive Etching (CARE), Plasma Assisted Polishing (PAP) and quartz crystal oscillator wafer processing systems. It has already received an order for a development unit related to next-generation polishing equipment and is also promoting joint development with major companies and others.」
The company is advancing commercialization and order-taking activities for equipment related to CARE, PAP and quartz crystal oscillator wafer processing systems as priority new fields, progressing to an order for a development unit for next-generation polishing equipment and joint development with major companies and others. - FY2023-Q1RestatedAnnual report
「For the second half of the fiscal year, the company plans to sell equipment in the priority areas of the Equipment Development Business, including equipment related to CARE, a new processing technology, and equipment related to the quartz crystal oscillator wafer processing system.」
Regarding the development of new fields in the Equipment Development Business, the company plans second-half sales of CARE-related equipment and equipment related to the quartz crystal oscillator wafer processing system as priority areas. - FY2022AdvancedAnnual report
「In addition, the company successfully commercialized a quartz crystal oscillator wafer processing system developed as a new business using its proprietary Plasma CVM processing technology and introduced it for uniform wafer-thickness processing.」
The quartz crystal oscillator wafer processing system was successfully commercialized and introduced for uniform wafer-thickness processing. The company is also developing polishing equipment for power semiconductors and semiconductor devices under CARE. - FY2022-Q3AdvancedAnnual report
「In the third quarter, sales associated with the Equipment Development Business, including evaluation-related work for vacuum ducts for kicker magnets and the URD manufacturing automation system, drove performance.」
Regarding the development of new fields in the Equipment Development Business, sales related to evaluation work for vacuum ducts for kicker magnets and the URD manufacturing automation system contributed to performance. The company continues to develop sales channels for the quartz crystal oscillator wafer processing system following delivery of the initial unit. - FY2022-Q2RestatedAnnual report
「In addition, the company continues to develop sales channels for the quartz crystal oscillator wafer processing system, which forms part of its new business, following its delivery in the previous fiscal year.」
The company has continued developing sales channels for the quartz crystal oscillator wafer processing system following its delivery in the previous fiscal year, with no significant change to its policy of developing new business fields in the Equipment Development Business. - FY2022-Q1RestatedAnnual report
「Over the medium to long term, the Company will promote sales of general-purpose equipment using the CELLFLOAT® system, while focusing on the equipment development business and cultivating new business fields within that business.」
The company has reaffirmed its medium- to long-term policy of focusing on the Equipment Development Business and developing new business fields. - FY2021-Q3Acceptance remained incomplete in the third quarter; completion targeted within the fiscal year.Annual report
「Meanwhile, system-wide optimization and final adjustments for the quartz crystal oscillator wafer processing system continued to take time, and acceptance was not completed during the third quarter. The company is making every effort to complete acceptance within the fiscal year.」
Acceptance of the quartz crystal oscillator wafer processing system was not completed during the third quarter. System optimization and final adjustments are continuing, with completion of acceptance targeted within the fiscal year. - FY2021-Q2Acceptance of the quartz crystal oscillator wafer processing system remains incomplete.Annual report
「Meanwhile, although the quartz crystal oscillator wafer processing system, for which sales had been scheduled in the second quarter, was delivered and commissioned after confirmation in the presence of the customer, and the specified accuracy was achieved, system-wide optimization and final adjustments took time, and acceptance was not completed during the second quarter.」
The quartz crystal oscillator wafer processing system progressed through delivery, commissioning and confirmation of the specified accuracy, but system optimization and final adjustments took time, preventing acceptance and revenue recognition in the scheduled second quarter. - FY2021-Q1Sales of the quartz crystal oscillator wafer processing system were delayed due to COVID-19.Annual report
「In addition, sales of the quartz crystal oscillator wafer processing system, whose development had been significantly delayed by the spread of COVID-19, are expected in the second quarter.」
Although the quartz crystal oscillator wafer processing system had been commercialized as a mass-production system, development was significantly delayed by the impact of COVID-19, and sales are now expected in the second quarter. - FY2020AdvancedAnnual report
「In particular, during the fiscal year, the company successfully commercialized a mass-production system by applying its Plasma CVM processing technology to the processing of quartz crystal oscillator wafers.」
Regarding the development of new fields in the Equipment Development Business, quartz crystal oscillator wafer processing progressed from prototype development to commercialization of a mass-production system. - FY2020-Q3AdvancedAnnual report
「In the third quarter, sales in the Equipment Development Business drove performance. Sales from contract development of equipment related to quartz crystal oscillator wafer manufacturing and sales of various gas detection systems drove performance.」
Contract development of equipment related to quartz crystal oscillator wafer manufacturing and sales of various gas detection systems contributed to actual revenue. In addition, significant sales of mass-production equipment for quartz crystal oscillator wafer processing are expected in the fourth quarter, indicating continued progress from prototype development to commercialization of mass-production equipment. - FY2020-Q2AdvancedAnnual report
「The factor behind the increase in the Life Science and Equipment Development Business is the expectation of significant sales of mass-production equipment for processing quartz crystal oscillator wafers. This project was a new business project in the Life Science and Equipment Development Business originally scheduled for the following fiscal year, but commercialization of the mass-production equipment was brought forward because prototype development progressed smoothly.」
For quartz crystal oscillator wafer processing, commercialization of mass-production equipment was brought forward from the following fiscal year as prototype development progressed, and the company reached the stage of anticipating sales of the mass-production equipment. - FY2020-Q1AdvancedAnnual report
「The company had not initially expected significant sales in the first quarter, and sales related to equipment development were substantial. These sales mainly came from prototype equipment for processing quartz crystal oscillator wafers and OEM sales of the gravure printing testing machine (GP-10).」
Regarding the development of new fields in the Equipment Development Business, prototype equipment for processing quartz crystal oscillator wafers and OEM sales of GP-10 contributed to actual revenue. - FY2019RestatedAnnual report
「Against this backdrop, the company will promote sales of general-purpose equipment using the CELLFLOAT® system over the medium to long term, while focusing going forward on the Equipment Development Business and the development of new business fields within that business.」
While sales penetration of general-purpose equipment has taken time and progress on some contract development projects has stalled, the company has reaffirmed its medium- to long-term policy of focusing on the Equipment Development Business and the development of new fields. - FY2019-Q3AdvancedAnnual report
「In the third quarter, sales in the Equipment Development Business drove performance. OEM sales of the gravure printing testing machine (GP-10) and design-fee revenue from a new automated cell culture system contributed to performance.」
Regarding the development of new fields in the Equipment Development Business, revenue was generated from OEM sales of GP-10 and design fees for a new automated cell culture system, demonstrating progress toward specific projects and revenue. - FY2019-Q2AdvancedAnnual report
「This project is a contract development project for manufacturing equipment commissioned by a major domestic company. The related revenue concerns the prototype development of manufacturing equipment for mass production that uses the company’s Plasma CVM technology, a surface nanomachining technology. The company will continue development toward manufacturing equipment for mass production.」
Regarding the development of new business fields in the Equipment Development Business, the company progressed to the stage of continuing development toward manufacturing equipment for mass production after receiving a contract from a major domestic company for prototype development of such equipment. - FY2019-Q1First statedAnnual report
「At the same time, the company has focused on developing new business fields in the Equipment Development Business.」
The company identifies its focus on developing new business fields in the Equipment Development Business as a new initiative.